PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION

Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.121
https://www.valueinhealthjournal.com/article/S1098-3015(18)33421-1/fulltext
Section Title :
Section Order : 642
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33421-1&doi=10.1016/j.jval.2018.09.121
HEOR Topics :
Tags :
Regions :